Icagen and Pfizer have initiated Phase I trials for a candidate compound,Nav 1.7.A sodium channel-blocker,Nav 1.7 is believed to have promise for the treatment of pain and related disorders.The early trials will ascertain the safety,tolerability,pharmokinetics and optimal formulation of Nav 1.7.
Pfizer is funding all aspects of the collaboration.The pharma titan has exclusive worldwide rights to commercialize any products resulting from the partnership.For its part,Icagen may receive milestones and tiered royalties based upon product sales.
Icagen,located in Research Triangle Park,North Carolina,has identified multiple drug candidates that modulate ion channels.Ions are charged particles such as sodium,potassium and calcium.Ion channels are protein structures that span cell membranes and regulate the flow of ions into and out of cells.
Icagen is focused on oral medications for epilepsy,pain and inflammation that work by modulating these ion channels.
Icagen(ICGN),Pfizer(PFE)
No comments:
Post a Comment